Gelonghui, December 12 | Kunming Pharmaceutical Group (600422.SH) is now up 7.2%, reaching a 2-month high of 17.23 yuan, with a total market value of 12.9 billion yuan. According to the latest report by Guosheng Securities, management integration, marketing adjustments, etc. were basically in place in the early stages of the reform of KPC, and they are optimistic about the gradual implementation of performance. 2025 is expected to be the first year of performance release. I am optimistic about the company's long-term development, covered for the first time, and given a “buy” rating. (Gelonghui)
A股异动丨昆药集团涨超7%创2个月新高 券商看好公司长期发展
A-share volatility丨KPC Pharmaceuticals, Inc. rises more than 7% to reach a two-month high. Brokerage is bullish on the company's long-term development.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated